A novel vaccine (Zostavax) to prevent herpes zoster

Giornale Italiano di Dermatologia e Venereologia

Volumn 143, Issue 2, 2008, Pages 119-123

  Holcomb, K ^a   Weinberg, J M ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Herpes zoster; Neuralgia, postherpetic; Vaccines

Indexed keywords

VARICELLA ZOSTER VACCINE;

CLINICAL TRIAL; ERYTHEMA; HEALTH CARE COST; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INJECTION SITE REACTION; MORBIDITY; NONHUMAN; PAIN; POSTHERPETIC NEURALGIA; PRURITUS; REVIEW; RHEUMATIC POLYMYALGIA; RISK FACTOR; SWELLING; UNSPECIFIED SIDE EFFECT;

EID: 45749084218     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Arvin A. Aging, immunity, and the varicella-zoster virus. N Engl J Med 2005;352:2266-7.
2. Wood MJ, Easterbrook P. Shingles, scourge of the elderly. The acute illness. In: Sacks SL, Straus SE, Whitley RJ, Griffiths PD, editors. Clinical management of herpes zoster. Washington, D.C.: IOS Press; 1995. pp. 193-209.
3. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352;2271-84.
4. Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T. Live vaccine use to prevent the spread of children in hospital. Lancet 1974;2:1288-90.
5. Breuer J. Vaccination to prevent varicella and shingles. J Clin Path 2001;54;743-7.
6. Kamiya H, Ito M. Update on varicella vaccine. Curr Opin Pediatr 1999;11:3-13.
7. Prevention of varicella: Update recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999;48:1-12.
8. Black S, Shinefield H, Ray P, Lewis E, Hansen J, Schwalbe J et al. Post-marketing evaluation of the safety and effectiveness of varicella vaccine. Pediatr Infect Dis J 1999;18:1041-6.
9. Vázquez M, Shapiro ED. Varicella vaccine and infection with varicella-zoster virus. N Engl J Med 2005;352;439-40.
10. Zhou F, Harpaz R, Jumaan AO, Winston CA, Shefer A. Impact of varicella vaccination on health care utilization. JAMA 2005;294;797-802.
11. Davis MM, Patel MS, Gebremariam A. Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States. Pediatrics 2004;114:786-92.
12. Miron D, Lavi I, Kitov R, Hendler A. Vaccine effectiveness and severity of varicella vaccine among previously vaccinated children during outbreaks in day care centers with low vaccination coverage. Pediatr Infect Dis J 2005;24:233-6.
13. Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JF. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis 2005;191:2002-7.
14. Hardy I, Gershon AA, Steinberg SP, LaRussa P The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. N Engl J Med 1991;325:1545-50.
15. Brunell PA, Taylor-Wiedeman J, Geiser CF, Frierson L, Lydick E. Risk of herpes zoster in children with leukemia: varicella vaccine compared with history of chickenpox. Pediatrics 1986;77:53-66.
16. Hammerschlag MR, Gershon AA, Steinberg SP, Clarke L, Gelb LD. Herpes zoster in an adult recipient of live attenuated varicella vaccine. J Infect Dis 1989;160:535-7.
17. Poland GA. The growing paradigm of preventing disease: vaccines to prevent herpes zoster and pertussis in adults. Ann Int Med 2005;143:539-41.
18. Chang MN, Guess HA, Heyse JF. Reduction in burden of illness: a new efficacy measure for prevention trials. Stat Med 1994;13:1807-14.
19. Guess HA, Lydick EG, Small RD, Miller LP. Epidemiologic programs for computers and calculators: exact binomial confidence intervals for the relative risk in follow-up studies with sparsely stratified incidence density data. Am J Epidemiol 1987;125:340-7.